Circulating asprosin levels in type 2 diabetes mellitus: A systematic review and meta-analysis
Roshan Kumar Mahat, Ashwini Manish Jantikar, Vedika Rathore, Suchismita Panda
Abstract
AimAsprosin, a recently discovered adipokine, exhibits pathological elevation in individuals experiencing insulin resistance. The aim of this systematic review and meta-analysis was to evaluate the association between circulating asprosin levels and type 2 diabetes mellitus.MethodsTwo independent authors carried out a thorough and systematic literature search of electronic databases including PubMed/Medline, Europe PMC, and Google Scholar for relevant studies published up to June 30, 2023. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated using random effect model. Cochran's Q test and I2 statistics were employed to assess the statistical heterogeneity. A leave-one-out sensitivity analysis was carried out to evaluate the stability of result and funnel plot was constructed to assess publication bias.ResultsTwenty-one articles including 1601 type 2 diabetes mellitus patients and 1162 healthy controls were selected for this systematic review and meta-analysis. Type 2 diabetes mellitus (T2DM) patients had significantly higher circulating asprosin levels compared to controls [SMD = 1.25, 95% CI: 0.89–1.61; p < 0.00001] with a considerable heterogeneity [I2 = 94%]. The results from subgroup analyses, which considered diagnostic criteria, study design, continents, sample size and type of blood sample, were consistent with the main finding.ConclusionCirculating asprosin levels were significantly increased in type 2 diabetes mellitus patients compared to controls. Hence, there is potential for utilizing asprosin as a target for therapeutic intervention in the treatment of type 2 diabetes mellitus.